University of Leicester researcher in potential medical breakthrough
“This new drug could be a game changer for future treatment of asthma” – Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester
The first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.
The research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as “a game changer for future treatment of asthma.”
Three people die every day because of asthma attacks and research shows that two thirds of asthma deaths are preventable, according to Asthma UK.
Fevipiprant (QAW039) significantly decreased the symptoms of asthma, improved lung function, reduced inflammation and repaired the lining of airways.
The drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma, according to ClinTrials.gov.
A total of 61 people took part in the research. One group was given 225mg of the drug twice a day for 12 weeks and the other participants were assigned to a placebo group. Fevipiprant and the placebo were added to the medications the participants were already taking.
The study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.
The sputum eosinophil is an inflammation measurement of a white blood cell that increases in asthma and is used to assess the severity of this condition.
People who do not have asthma have a percentage of less than one and those with moderate-to-severe asthma typically have a reading of about five per cent.
The rate in people with moderate-to-severe asthma taking the medication was reduced from an average of 5.4 percent to 1.1 percent over 12 weeks, according to the study published today in the prestigious The Lancet Respiratory Medicine journal.
Professor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.
Professor Brightling said: “A unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works.
“Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.
“We already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.
“This new treatment, Fevipiprant, could likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms- making it a ‘game changer’ for future treatment.”
Gaye Stokes from Grantham in Lincolnshire has had severe asthma for 16 years. She took part in the trial and was part of the Fevipiprant group.
The 54-year-old said: “I knew straight away that I had been given the drug. I felt like a completely different person. I had more get up and go, I was less wheezy and for the first time in years I felt really, really well.
“For me, it felt like a complete wonder drug and I can’t wait for it to be available because I really think it could make a huge difference to me.”
After the 12 week trial and Gaye stopped receiving the drug, she said her health started to “go downhill again very quickly”.
Professor Brightling added that the latest advance underpinned the work of the Leicester Precision Medicine Institute, a Centre of Excellence that coalesces and aligns the research missions of the University of Leicester and the NHS in Leicester.
Future treatment of human disease will increasingly move from a ‘one size fits all’ approach to one of tailoring the treatment to the individual patient.
Asthma is a long-term condition that affects the airways. When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.
The NIHR Leicester Respiratory Biomedical Research Unit – a partnership between the University of Leicester and Leicester’s Hospitals – focuses on promoting the development of new and effective therapies for the treatment of respiratory diseases including severe asthma and chronic obstructive pulmonary disease (COPD).
The Latest on: Asthma pill
via Google News
The Latest on: Asthma pill
- Arab Health to address asthma issues in Menaon December 10, 2019 at 2:05 am
Arab Health, a major healthcare trade fair in the Mena region, will address the growing prevalence of asthma in the region as part of the 4th annual Emergency Medicine Conference, taking place on the ...
- Cold weather potentially dangerous for people with asthmaon December 9, 2019 at 3:08 pm
On any cold day, Brie takes her daily medication at a higher dose. Taking precautionary measures has prevented Brie from ever having an asthma attack. The Lung Association suggests staying bundled in ...
- BRIEF-Novartis Says Phase III Data On Asthma Drug QMF149 Shows Significant Improvementon December 5, 2019 at 10:32 pm
Our Standards:The Thomson Reuters Trust Principles.
- A multinational observational study identifying primary care patients at risk of overestimation of asthma controlon December 5, 2019 at 3:19 am
Significant differences were noted in age, gender, body mass index, education level, medication use, side effects, attitudes to preventer inhaler use, inhaler technique review and respiratory ...
- Lung images of twins with asthma add to understanding of the diseaseon December 4, 2019 at 9:56 am
researchers used a specialized MRI technique developed at Western's Schulich School of Medicine & Dentistry, to follow 11 patients with mild to moderate asthma over a six year period and were able ...
- Bidirectional association between asthma and migraines in adults: Two longitudinal follow-up studieson December 4, 2019 at 2:21 am
For the classifications of asthma and migraine, both diseases were diagnosed by physicians twice or more, and medication prescriptions were checked for asthma. Moreover, migraines were classified ...
- Asthma attacks in pregnancy tied to complications for mothers, babieson December 3, 2019 at 1:44 pm
Asthma attacks during pregnancy are associated with an increased risk of complications for mothers and their babies, a Canadian study suggests. Researchers examined data on more than 103,000 ...
- Prenatal Asthma Attacks Up Complications for Mom and Babyon December 3, 2019 at 1:42 pm
Pregnant women who have asthma need regular antenatal care to discuss their symptoms and ensure their medication is effective," Vestbo stressed. The study was supported by the Institute for Clinical ...
- Uncontrolled Asthma a Danger to Pregnant Women, Babieson December 3, 2019 at 12:23 pm
The findings are important because up to 40% of women with asthma cut back or stop taking asthma medication during pregnancy because they're afraid it will harm the unborn baby, according to the ...
- Knopp Biosciences and University of Leicester Announce Update on Planned Phase 2 Clinical Trial of Oral Dexpramipexole in Severe Eosinophilic Asthmaon December 2, 2019 at 3:20 am
... with world-renowned asthma investigators in the UK to assess the effects of oral dexpramipexole on asthma exacerbations,” said Michael Bozik, M.D., president and CEO of Knopp. “An unmet need ...
via Bing News